Sorafenib and sunitinib reduce tumour-cell proliferation and angiogenesis by acting as small-molecule inhibitors of multiple kinases; vegf receptors 1, 2, and 3; pdgf beta receptors; and fms-like tyrosine kinase 3 (Flt3), among others 46. Here, FLT3 is linked to neoplasm.